Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up ...

The US Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki ... Boxed Warning detailing the risk of interstitial lung disease and embryo-fetal toxicity.

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Paget Disease of Bone. According to GlobalData, Phase I drugs for Paget Disease of Bone does not ...

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative ...

The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.

One of the most notable studies compared trastuzumab deruxtecan ... particularly interstitial lung disease and pneumonitis, which necessitates careful monitoring[1][3][5]. In a broader context ...

Sacituzumab govitecan (Trodelvy) appears to have more severe cytopenias and diarrhea. However, Dato-DXd and trastuzumab deruxtecan (T-DXd; Enhertu) may have more instances of interstitial lung disease ...

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy ...

In the DATROWAY arm, the interstitial lung disease (ILD) rate was 4.2% and the majority of events were low grade ... mechanisms of action to address the biologically diverse breast cancer tumor ...

Were you aware of the 43-month follow-up data from the DESTINY-Breast03 trial (NCT03529110) of trastuzumab deruxtecan (T-DXd, Enhertu ... I’ve used it. I haven't seen any interstitial lung disease ...

In the DATROWAY arm, the interstitial lung disease (ILD ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except ...